Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

Taking into account higher risk of severe coronavirus disease 2019 or death among patients with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in addition to waning immunity, booster dosing appears mandatory in this patient population. This review sought to provide reason...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrière, Jérôme, Carles, Michel, Audigier-Valette, Clarisse, Re, Daniel, Adjtoutah, Zoubir, Seitz-Polski, Barbara, Gounant, Valérie, Descamps, Diane, Zalcman, Gérard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674546/
https://www.ncbi.nlm.nih.gov/pubmed/35016032
http://dx.doi.org/10.1016/j.ejca.2021.12.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674546/
https://www.ncbi.nlm.nih.gov/pubmed/35016032
http://dx.doi.org/10.1016/j.ejca.2021.12.011

Ejemplares similares